Medicare reimbursement should be based on the "value" of medicines, not their price, incoming Centers for Medicare & Medicaid Services Administrator Mark McClellan told the Senate Finance Committee in a 1written Q&A exchange
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.
During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.
US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.
